Market by Therapeutics, Diagnostics, and Country Outlook | Forecast 2022-2028
A
report by Triton Market Research shows that the market for Alzheimer’s disease
therapeutics and diagnostics in the Middle East and Africa will grow with a CAGR of 5.81% in the forecast duration 2022-2028.
Report scope can be customized per your requirements. Request For Customization
The countries scrutinized in
this market include:
• Turkey
• South Africa
• The United Arab Emirates
• Saudi Arabia
• Rest of Middle East & Africa
Several
countries in the Middle East are preferred destinations for medical tourism, which
has led to increased investments and attracted the attention of leading market
players to the region, especially the UAE and Saudi Arabia. However, in the
African nations, Alzheimer’s does not receive much attention due to the lack of
awareness, infrastructure, and skilled professionals in this field. Overall,
the growing elderly population is expected to enhance the need for therapeutics
and diagnostics for Alzheimer’s disease in the region.
Latest
statistics indicate that close to 400,000 people in Turkey are affected by AD. The
establishment of institutions like the Turkish Alzheimer Society and Turkish
Alzheimer Foundation, which are working to raise the disease’s awareness and
improve the treatment and care offered to Alzheimer’s disease patients, is
expected to foster the market’s growth.
In
the United Arab Emirates, various government-affiliated institutions, as well
as NGOs, are initiating programs to increase awareness regarding Alzheimer’s
disease, which is expected to positively influence the demand for AD
therapeutics and diagnostics. For instance, the Ministry of Health and
Prevention, in September 2020, organized several activities for World Alzheimer’s
Day to raise public awareness about the importance of early disease diagnosis
and treatment.
The
increased healthcare spending has resulted in the higher adoption of advanced
diagnostic methods for AD treatment. Positron emission tomography (PET) is one
such technique, which uses a computer, a camera, and small amounts of
radioactive materials known as radiotracers to evaluate organ and tissue
malfunctions in the diagnosis process. A PET scan detects and records a
significantly larger percentage of emitted rays. Additionally, PET scanners facilitate
easy diagnosis, owing to numerous advantages, which is expected to increase the
demand for positron emission tomography.
The report assesses the market
according to diagnostics and therapeutics. Here,
the diagnostics segment comprises positron emission tomography, lumbar puncture
test, blood test, computed tomography, electroencephalography, magnetic
resonance imaging, and other diagnostics.
Some of the notable companies
in the Alzheimer’s disease therapeutics and diagnostics market are Johnson and
Johnson, Lupin Limited, Biogen Inc, Pfizer Inc, F. Hoffmann-La Roche AG,
Novartis AG, Allergan Plc (acquired by Abbvie), Amarantus Bioscience Holdings
Inc, and GE Healthcare.
Teva Pharmaceutical Industries Ltd is a leading company with a primary focus on generic drugs, active pharmaceutical ingredients (API), and proprietary pharmaceuticals to a certain extent. It is the world’s largest generic medicine manufacturer. The company manufactures solid dosage forms, semi-solids, liquids, sterile injectables, transdermal patches, inhalers, and other medical devices. Teva Pharmaceutical offers Donepezil and Quetiapine for Alzheimer’s treatment. Founded in 1935, the company is headquartered in Petach Tikva, Israel.
Key deliverables of the
report:
·
Market
CAGR during the forecasting years 2022-2028
·
Detailed
data highlighting key insights, industry components, and market strategies
·
Comprehensive
information and estimation of the Alzheimer’s disease therapeutics and diagnostics
market revenue growth in the Middle East and Africa and its influence on the
parent market
·
In-depth
study of forthcoming trends in consumer behavioral patterns
·
A
meticulous analysis of the competitive landscape, vendor scorecard, and
Porter’s Five Forces Model
·
A
wide-ranging study of factors that will challenge the Middle East and Africa Alzheimer’s
disease therapeutics and diagnostics market’s growth during the upcoming years
Want
to get specific insights? Our team of analysts can customize this report based
on your preferences. Connect with us here.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET –
SUMMARY
2. INDUSTRY
OUTLOOK
2.1. TIMELINE
OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.2. PHASES
AND STERNNESS OF ALZHEIMER’S DISEASE
2.3. KEY
INSIGHTS
2.3.1. USAGE
OF COMPUTED TOMOGRAPHY FOR THE DIAGNOSIS OF ALZHEIMER’S DISEASE
2.3.2. R&D
INVESTMENTS IN BIOMARKERS FOR EARLY DETECTION OF DEMENTIA
2.3.3. DEMAND
FOR PERSONALIZED MEDICINES
2.4. IMPACT
OF COVID-19 ON THE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
2.5. PORTER’S
FIVE FORCES ANALYSIS
2.6. MARKET
ATTRACTIVENESS MATRIX
2.7. VENDOR
SCORECARD
2.8. INDUSTRY
COMPONENTS
2.8.1. RESEARCH
& DEVELOPMENT (R & D)
2.8.2. RAW
MATERIALS
2.8.3. MANUFACTURING
2.8.4. DISTRIBUTORS/WHOLESALERS/RETAILERS
2.8.5. END-USER
2.9. KEY
IMPACT ANALYSIS
2.9.1. EFFECTIVENESS
2.9.2. PRICE
2.9.3. SAFETY
2.10. KEY
MARKET STRATEGIES
2.10.1. ACQUISITIONS
2.10.2. PRODUCT
LAUNCHES
2.10.3. CONTRACTS
& AGREEMENTS
2.10.4. INVESTMENTS
& EXPANSIONS
2.11. MARKET
DRIVERS
2.11.1. PREVALENCE
OF ALZHEIMER’S DISEASE
2.11.2. RISE
IN THE ELDERLY POPULATION
2.12. MARKET
CHALLENGES
2.12.1. FAILURE
OF LATE-STAGE DRUGS
2.12.2. STRINGENT
GOVERNMENT REGULATIONS
2.13. MARKET
OPPORTUNITIES
2.13.1. EMERGENCE
OF NEW DIAGNOSTIC TECHNOLOGIES
2.13.2. GROWING
NUMBER OF PIPELINE DRUGS
3. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
THERAPEUTICS
3.1. BY
DRUG TYPE
3.1.1. MARKETED
DRUGS
3.1.2. PIPELINE
DRUGS
3.2. BY
DISEASE STAGE
3.2.1. LATE
STAGE: SEVERE AD
3.2.2. EARLY/MIDDLE
STAGE: MILD TO MODERATE AD
3.2.3. PRODROMAL
STAGE
3.3. BY
GENERIC & BRANDED
3.3.1. BRANDED
3.3.2. GENERIC
4. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET – BY
DIAGNOSTICS
4.1. LUMBAR
PUNCTURE TEST
4.2. POSITRON
EMISSION TOMOGRAPHY
4.3. ELECTROENCEPHALOGRAPHY
4.4. MAGNETIC
RESONANCE IMAGING
4.5. COMPUTED
TOMOGRAPHY
4.6. BLOOD
TEST
4.7. OTHER
DIAGNOSTICS
5. MIDDLE
EAST AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET –
COUNTRY OUTLOOK
5.1. UNITED
ARAB EMIRATES
5.2. TURKEY
5.3. SAUDI
ARABIA
5.4. SOUTH
AFRICA
5.5. REST
OF MIDDLE EAST & AFRICA
6. COMPETITIVE
LANDSCAPE
6.1. BAXTER
INTERNATIONAL INC
6.2. F.
HOFFMANN-LA ROCHE AG
6.3. ALLERGAN
PLC (ACQUIRED BY ABBVIE)
6.4. NOVARTIS
AG
6.5. PFIZER
INC
6.6. SIEMENS
HEALTHINEERS AG
6.7. AMARANTUS
BIOSCIENCE HOLDINGS INC
6.8. EISAI
CO LTD
6.9. ELI
LILLY & COMPANY
6.10. LUPIN
LIMITED
6.11. MERCK
AND CO
6.12. BIOGEN
INC
6.13. COGNOPTIX
INC
6.14. GE
HEALTHCARE
6.15. JOHNSON
AND JOHNSON
6.16. SUN
PHARMACEUTICALS INDUSTRIES LTD
6.17. TEVA
PHARMACEUTICAL INDUSTRIES LTD
6.18. ZYDUS
CADILA
7. METHODOLOGY
& SCOPE
7.1. RESEARCH
SCOPE
7.2. SOURCES
OF DATA
7.3. RESEARCH
METHODOLOGY
TABLE 1: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: MARKET
ATTRACTIVENESS MATRIX
TABLE 3: VENDOR
SCORECARD
TABLE 4: KEY STRATEGIC
DEVELOPMENTS
TABLE 5: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2022-2028 (IN $ MILLION)
TABLE 6: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2022-2028 (IN
$ MILLION)
TABLE 7: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2022-2028
(IN $ MILLION)
TABLE 8: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED,
2022-2028 (IN $ MILLION)
TABLE 9: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2022-2028 (IN $ MILLION)
TABLE 10: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: PORTER’S FIVE
FORCES ANALYSIS
FIGURE 2: KEY IMPACT ANALYSIS
FIGURE 3: TIMELINE OF
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
FIGURE 4: INDUSTRY
COMPONENTS
FIGURE 5: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
THERAPEUTICS, 2021 & 2028 (IN %)
FIGURE 6: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DRUG TYPE, 2021 &
2028 (IN %)
FIGURE 7: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY MARKETED DRUGS,
2022-2028 (IN $ MILLION)
FIGURE 8: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PIPELINE DRUGS,
2022-2028 (IN $ MILLION)
FIGURE 9: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY DISEASE STAGE, 2021
& 2028 (IN %)
FIGURE 10: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD,
2022-2028 (IN $ MILLION)
FIGURE 11: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD
TO MODERATE AD, 2022-2028 (IN $ MILLION)
FIGURE 12: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY PRODROMAL STAGE,
2022-2028 (IN $ MILLION)
FIGURE 13: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC & BRANDED,
2021 & 2028 (IN %)
FIGURE 14: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY BRANDED, 2022-2028 (IN $
MILLION)
FIGURE 15: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS MARKET, BY GENERIC, 2022-2028 (IN $
MILLION)
FIGURE 16: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY
DIAGNOSTICS, 2021 & 2028 (IN %)
FIGURE 17: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST,
2022-2028 (IN $ MILLION)
FIGURE 18: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY POSITRON EMISSION
TOMOGRAPHY, 2022-2028 (IN $ MILLION)
FIGURE 19: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 20: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE
IMAGING, 2022-2028 (IN $ MILLION)
FIGURE 21: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY,
2022-2028 (IN $ MILLION)
FIGURE 22: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY BLOOD TEST, 2022-2028 (IN
$ MILLION)
FIGURE 23: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS,
2022-2028 (IN $ MILLION)
FIGURE 24: MIDDLE EAST
AND AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY
OUTLOOK, 2021 & 2028 (IN %)
FIGURE 25: UNITED ARAB
EMIRATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN
$ MILLION)
FIGURE 26: SAUDI ARABIA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 27: TURKEY
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 28: SOUTH AFRICA
ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET 2022-2028 (IN $
MILLION)
FIGURE 29: REST OF
MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
MARKET 2022-2028 (IN $ MILLION)